Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660 on ClinicalTrials.gov · last registry update 2026-03-05
Finished 22 January 2026, after enrolling 537 people. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c) (%). retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P3
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 537
- Started
- 2024-04-10
- Primary completion
- 2026-01-22 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Conditions studied
Diabetes Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.